11 recruiting, 6 unknown, 4 not yet recruiting, 3 completed. 9 Phase 1, 5 Not applicable, 5 Phase 2, 2 Early Phase 1, 1 Phase 3.
Follow Inflammatory Myopathy: new trials by email Literature Review of Inflammatory Myopathy trials Research Report on Inflammatory Myopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases UCAR-T cells - Systemic Lupus Erythematosus, Inflammatory Myopathy | Early Phase 1 | Withdrawn | The Affiliated Hospital of Xuzhou Medical University | 2026-03-01 | 2026-05-28 | |
| TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM) Telitacicept 240mg - Inflammatory Myopathy | Phase 2 / Phase 3 | Not yet recruiting | Zhongming Qiu | 30 | 2026-02-02 | 2026-01-21 |
| A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases TI-0032-III injection - Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS) | Phase 1 | Recruiting | Therorna | 12 | 2026-01-22 | 2026-10-19 |
| An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus, Lupus Nephritis (LN) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-11-24 | 2026-03-04 |
| Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-11-13 | 2026-03-02 |
| A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-08-13 | 2026-10-21 |
| A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-08-04 | 2026-10-21 |
| MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS) No intervention - qualitative and mixed methods investigations - IBM, IIM | Recruiting | Myositis International Health & Research Collaborative Alliance Foundation | 700 | 2025-06-25 | 2026-01-28 | |
| A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 12 | 2025-05-19 | 2026-10-21 |
| UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases universal allogeneic anti-CD19/BCMA CAR T-cells - Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia | Phase 1 | Not yet recruiting | Changzhou No.2 People's Hospital | 18 | 2025-05-01 | 2025-05-18 |
| BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-T - Inflammatory Myopathy | Phase 1 | Recruiting | iCell Gene Therapeutics | 10 | 2025-03-20 | 2026-07-20 |
| CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases UCAR T-cell - Systemic Lupus Erythematosus, Systemic Sclerosis (SSc) | Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 12 | 2025-02-11 | 2025-09-29 |
| Virtual Reality and Robotics in Inflammatory Myopathy Rehabilitation Non-immersive virtual reality, Standard physical therapy - Inflammatory Myopathy | Not applicable | Completed | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | 33 | 2025-02-11 | 2026-04-01 |
| BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases BCMA-CD19 CAR-T therapy - Systemic Lupus Erythematosus, Inflammatory Myopathy | Phase 2 | Recruiting | Peking University People's Hospital | 50 | 2024-12-26 | 2025-04-02 |
| An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease YTS109 - Systemic Lupus Erythematosus, Systemic Sclerosis | Not applicable | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 6 | 2024-10-24 | 2026-10-22 |
| The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases anti-CD19-CAR-T cells - Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome | Early Phase 1 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 9 | 2024-05-27 | 2024-05-17 |
| Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Anti-CD19-CD3E-CAR-T cells - Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome | Not applicable | Unknown | Shanghai Changzheng Hospital | 6 | 2024-04-20 | 2024-04-18 |
| Renal Manifestations During Idiopathic Inflammatory Myopathies Inflammatory Myopathy | Unknown | University Hospital, Strasbourg, France | 15 | 2024-01-05 | 2025-04-01 | |
| Adult Idiopathic Inflammatory Myopathy With Cardiac Injury Inflammatory Myopathy, Cardiac Disease | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 300 | 2024-01-01 | 2023-10-17 | |
| Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases BRL-301 - Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome | Not applicable | Enrolling by invitation | Bioray Laboratories | 15 | 2023-05-17 | 2024-11-20 |
Showing 20 of 26. Sign in to see all of them.
Myositis (26) · Lupus Erythematosus, Systemic (15) · Scleroderma, Systemic (12) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (11) · Antiphospholipid Syndrome (10) · Sjogren's Syndrome (10) · Arthritis, Rheumatoid (3) · Autoimmune Diseases (3) · Dermatomyositis (3) · Immunoglobulin G4-Related Disease (3) · Lupus Nephritis (3) · Behcet Syndrome (2) · Polymyositis (2) · Recurrence (2) · Spondylarthritis (2)
Muscular Diseases (26) · Musculoskeletal Diseases (26) · Nervous System Diseases (26) · Neuromuscular Diseases (26) · Connective Tissue Diseases (18) · Skin and Connective Tissue Diseases (18) · Skin Diseases (17) · Immune System Diseases (16) · Cardiovascular Diseases (15) · Vascular Diseases (14) · Autoimmune Diseases (13) · Skin Diseases, Vascular (13) · Vasculitis (13) · Systemic Vasculitis (12) · Arthritis (11)
Interleukin-2 (2) · aldesleukin (2) · Adrenal Cortex Hormones (1) · Cyclosporine (1) · Serologic Tests (1) · Valsartan (1) · Yellow Fever Vaccine (1) · sacubitril and valsartan sodium hydrate drug combination (1) · telitacicept (1)
China Immunotech (Beijing) Biotechnology Co., Ltd. (6) · Peking University People's Hospital (3) · Benha University (1) · Bioray Laboratories (1) · Changzhou No.2 People's Hospital (1) · First Affiliated Hospital of Wenzhou Medical University (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Mark Ledwidge (1) · Myositis International Health & Research Collaborative Alliance Foundation (1) · National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland (1) · Shanghai Changzheng Hospital (1) · The Affiliated Hospital of Xuzhou Medical University (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Therorna (1) · University Hospital, Strasbourg, France (1)
China (15) · Brazil (1) · Egypt (1) · France (1) · Ireland (1) · Poland (1) · Tunisia (1) · United States (1)
Zhanguo Li (3) · Aleksandra Markowska (1) · Beata Tarnacka, Professor (1) · Eloisa Bonfa, MD, PhD (1) · Faida Ajili, MD (1) · Fiona Ryan, Co-Investigator, PhD (1) · Huji Xu, MD,Ph.D (1) · Huji Xu, Ph.D, MD (1) · LI Sun, Master's (1) · Lesley Ann Saketkoo, MD, MPH (1) · Waleed Hassan, MD (1)
PMID 327194, PMID 33852146, PMID 34843469, PMID 36884247, PMID 39013470, PMID 40446794, PMID 40866583, PMID 42349572
2015 (1)